Hypermutations in gliomas: a potential immunotherapy target

Area of Science:

• Oncology
• Immunology
• Genetics

Background:

• Cancer immunotherapy utilizing checkpoint inhibitors has shown significant success in various cancers like melanoma, colorectal, and lung cancer.
• Tumor mutational load is closely linked to patient response to checkpoint inhibitor immunotherapy.
• Hypermutations can arise from environmental factors or germline mutations in DNA Mismatch Repair (MMR) genes, as seen in Lynch syndrome.

Purpose of the Study:

• To explore the potential of immunotherapy in treating low- and high-grade gliomas, the most common brain tumors.
• To investigate the role of temozolomide-induced hypermutations in gliomas and their susceptibility to immunotherapy.
• To determine if immunotherapy can improve survival outcomes for glioma patients with specific genetic profiles.

Main Methods:

• Review of existing research on cancer immunotherapy, mutational load, and MMR gene defects.
• Analysis of the frequency of hypermutations in gliomas, particularly after temozolomide treatment.
• Examination of the association between MMR gene status, MGMT methylation, and tumor response to therapy.

Main Results:

• Germline MMR defects are uncommon in gliomas, but acquired hypermutations due to MMR gene alterations or reduced expression occur in 20-60% of recurrent tumors.
• Temozolomide chemotherapy, especially when MGMT is methylated, can induce hypermutations in gliomas.
• The presence of a high mutational load increases neoantigen presentation, potentially enhancing T cell responses.

Conclusions:

• Gliomas with temozolomide-induced hypermutations may represent a targetable population for immunotherapy.
• Ongoing clinical trials and genomic studies are crucial to validate the efficacy of checkpoint inhibitors and dendritic cell immunotherapy in these patients.
• Immunotherapy holds promise for improving survival expectations in glioma patients with specific hypermutated profiles.